What does this research mean for the field?

Elevated cardiometabolic index (CMI) is significantly associated with the progression of cardiovascular–kidney–metabolic syndrome stages in a Chinese population. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study aims to examine the relationship between cardiometabolic index (CMI) and stage progression in cardiovascular-kidney-metabolic syndrome (CKM).

February 2, 2026Open Access

Association between cardiometabolic index and stage progression in cardiovascular–kidney–metabolic syndrome: insights from a Chinese population-based cohort study

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Cardiovascular-kidney-metabolic syndrome (CKM) (n=4080). Intervention: Elevated cardiometabolic index (CMI) vs. Lower cardiometabolic index. Primary outcome: Progression to CKM stages 2-4 among participants at baseline CKM stages 0-1 (OR 1.66, 95% CI 1.32-2.11, p=<0.001).

Key Result

Elevated cardiometabolic index significantly predicted progression to advanced cardiovascular-kidney-metabolic syndrome stages, with an adjusted OR of 1.66 for progression to stages 2-4 among those at baseline stages 0-1.

Key Points

The study aims to examine the relationship between cardiometabolic index (CMI) and stage progression in cardiovascular-kidney-metabolic syndrome (CKM).
Population-based cohort study conducted in a Chinese population.
Assessment of cardiometabolic index (CMI) levels in participants.
Longitudinal follow-up to track CKM stage progression over time.
Higher CMI is significantly linked to increased stage progression of CKM.
CMI shows potential as a simple tool for assessing CKM risk.

Study Design

Type

Cohort (n=4,080)

Multicenter

Yes

Structured PICO

Does an elevated cardiometabolic index (CMI) predict the progression of cardiovascular-kidney-metabolic (CKM) syndrome stages in middle-aged and older adults?

Population

4,080 middle-aged and older Chinese adults (mean age 59 years, 53.7% female) free of stage 4 cardiovascular-kidney-metabolic syndrome at baseline, followed for 4 years.

Exposure

Elevated Cardiometabolic Index (CMI), calculated as [waist circumference (cm)/height (cm)] × [triglycerides (mg/dL)/high-density lipoprotein cholesterol (mg/dL)], evaluated as a continuous variable (Ln[CMI]) and in quartiles.

Comparator

Lower Cardiometabolic Index (CMI) values (e.g., lowest quartile Q1)

Outcome

Progression of Cardiovascular-Kidney-Metabolic (CKM) syndrome stages from Wave 1 (2011) to Wave 3 (2015)composite

Elevated cardiometabolic index is a significant longitudinal predictor of cardiovascular-kidney-metabolic syndrome stage progression, suggesting its utility as a simple risk assessment tool.

Main Result

Odds Ratio: 1.66 (95% CI 1.32–2.11)

p-value: p=<0.001

Limitations

Lack of urine albumin-to-creatinine ratio testing among participants limited CKD risk stratification.
Exclusion of a large number of participants due to missing data required for CKM staging may introduce selection bias.
Relatively small sample size for the CKM stage 0 subgroup limited statistical power to detect associations in that specific group.

Abstract

Elevated CMI is significantly associated with CKM stage progression over time. CMI could act as a simple, useful tool for the risk assessment of CKM.

AI에게 질문

Bookmark

View Full Paper

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Lyu et al. (Thu,) conducted a cohort in Cardiovascular-kidney-metabolic syndrome (CKM) (n=4,080). Elevated cardiometabolic index (CMI) vs. Lower cardiometabolic index was evaluated on Progression to CKM stages 2-4 among participants at baseline CKM stages 0-1 (OR 1.66, 95% CI 1.32-2.11, p=<0.001). Elevated cardiometabolic index significantly predicted progression to advanced cardiovascular-kidney-metabolic syndrome stages, with an adjusted OR of 1.66 for progression to stages 2-4 among those at baseline stages 0-1.

synapsesocial.com/papers/6980fc17c1c9540dea80df19 https://doi.org/https://doi.org/10.1186/s40001-026-03910-2

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: